BELKIN Laser is developing a contact-free laser procedure for the primary treatment of glaucoma.

The device delivers a single laser beam, with a pulse duration of a few nanoseconds, 120 times in about a second to the limbus, enhancing intraocular fluid drainage and lowering intraocular pressure, a key risk factor for glaucoma.

Suitable for use in clinics and hospitals, this technology serves as an initial or adjunctive treatment for glaucoma, including both open angle and angle closure types.The company received FDA Clearance for the Eagle Device.